1 |
Marrie TJ, Lau CY, Wheeler SL, A Controlled Trial of a Critical Pathway for Treatment of Community-acquired Pneumonia, Journal of the American Medical Association 2000; 283: 749-755.
DOI
ScienceOn
|
2 |
Tillotson, g. s. Quinolones: Structure-activity Relationship and Future Predictions, Journal of Medical Biology 1996; 44: 320-4.
|
3 |
Joseph M. Blondeau. A Review of the Comparative invitro Activities of 12 Antimicrobial Agents, with a Focus on Five New Respiratory Quinolones, Journal of Antimicribial Chemotherapy 1999; 43: 1-11.
|
4 |
Marrie TJ. Experience with Levofloxacin in a Critical Pathway for the Treatment of Community-acquired Pneumonia,Chemotherapy. 2004; 50(suppl 1): 11-15.
|
5 |
Nelson, JM.; Chiller, TM.; Powers, JH.; Angulo, FJ. Fluoroquinolone-resistant Campylobacter Species and the Withdrawal of Fluoroquinolones from Use in Poultry: a Public Health Success Story. (PDF), Clinical Infectious Diseases 2007; 44(7): 977-80.
DOI
ScienceOn
|
6 |
Robicsek A, Jacoby GA, Hooper DC. The Worldwide Emergence of Plasmid-mediated Quinolone Resistance, Lancet Infectious Disease 2006; 6(10): 629-40.
DOI
ScienceOn
|
7 |
Ppin J, Saheb N, Coulombe MA, et al., J . Emergence of Fluoroquinolones as the Predominant Risk Factor for Clostridium difficile-associated Diarrhea: a Cohort Study during an Epidemic in Quebec, Clinical Infectious Diseases 2005; 41(9): 1254-60.
DOI
ScienceOn
|
8 |
Robert P. Fluoroquinolone Positioning in Hospital Antimicrobial Stepwadrship Programs, Pharmacists' online information resource 2007; 32: 12
|
9 |
Rosemary R. Berardi, Pharm D, FCCP, FASHP Professor of Pharmacy, Department of Clinical Science, The University of Michigan Colledge of Pharmacy, Ann Arbor Handbook of Nonprescription Drugs - an interactive approach to selfcare 14th edition. 2006; American Pharmacists Association.
|
10 |
홍주형, 유지숙, 이길호. Ciprofloxacin 약제에 내성을 보이는 대장균에 의한 소아요로감염: 위험 인자 분석 Korean Journal of Urology 2009; 50(12): 1219-1224.
DOI
ScienceOn
|
11 |
Judith A, Aberg, Morton P. Goldman, Larry D. Gray, Jennifer K. Long(2006), Infectious Diseases Handbook, 6th Edition, Ohio, Lexi-Comp, Inc.
|
12 |
Carrie, Ag; Kozyrskyj, Al. Outpatient Treatment of Community-acquired Pneumonia: Evolving Trends and a Focus on Fluoroquinolones. (PDF), The Canadian Journal of Clinical Pharmacology 2006; 13(1): e102-11.
|
13 |
Jacobs M. Worldwide Overview of Antimicrobial Resistance. International Symposium on Antimicrobial Agents and Resistance 2005.
|
14 |
Lescher, G. Y., Forelich, E. D., Gruet, M. D., Bailey, H. J. and Brundage, R. P. 1, 8-Naphthyridine Derivatives: a New Class of Chemotherapeutic Agents, Journal of Medical Phamaceutical Chemistry 1962; 5: 1063-8.
DOI
|
15 |
Linder JA, Huang ES, Steinman MA, Gonzales R, Stafford RS. Fluoroquinolone Prescribing in the United States: 1995 to 2002, The American Journal of Medicine 2005; 118(3): 259-68.
DOI
ScienceOn
|
16 |
Liu, H.; Mulholland, SG. Appropriate Antibiotic Treatment of Genitourinary Infections in Hospitalized Patients. The American Journal of Medicine 2005; 118 Suppl 7A: 14S-20S.
|
17 |
MacDougall C, Guglielmo BJ, Maselli J, Gonzales R. Antimicrobial Drug Prescribing for Pneumonia in Ambulatory Care, Emerging Infectious Diseases 2005; 11 (3): 380-4.
DOI
|